Medacta Group SA (MEDGF)
83.91
0.00 (0.00%)
USD |
OTCM |
Apr 23, 16:00
Medacta Group Cash from Investing (TTM): -87.38M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -87.38M |
| June 30, 2023 | -76.17M |
| December 31, 2022 | -68.12M |
| June 30, 2022 | -70.61M |
| December 31, 2021 | -61.00M |
| June 30, 2021 | -45.36M |
| Date | Value |
|---|---|
| December 31, 2020 | -38.91M |
| June 30, 2020 | -40.03M |
| December 31, 2019 | -46.97M |
| June 30, 2019 | -42.36M |
| December 31, 2018 | -58.18M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-87.38M
Minimum
Dec 2023
-38.91M
Maximum
Dec 2020
-57.69M
Average
-53.99M
Median
Cash from Investing (TTM) Benchmarks
| AC Immune SA | 73.11M |
| CRISPR Therapeutics AG | 374.65M |
| Addex Therapeutics Ltd | -0.0076M |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | 49.71M |